Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

ClinicalTrials.gov ID: NCT00163514

Public ClinicalTrials.gov record NCT00163514. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

Study identification

NCT ID
NCT00163514
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
636 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2004
Primary completion
Jun 30, 2005
Completion
Jun 30, 2005
Last update posted
Dec 1, 2016

2004 – 2005

United States locations

U.S. sites
58
U.S. states
26
U.S. cities
55
Facility City State ZIP Site status
Altana Pharma/Nycomed Oxford Alabama 36203
Altana Pharma/Nycomed Huntington Beach California 92647
Altana Pharma/Nycomed Mission Viejo California 92691
Altana Pharma/Nycomed Newport Beach California CA 92660
Altana Pharma/Nycomed Orange California 92868
Altana Pharma/Nycomed Palmdale California 93551
Altana Pharma/Nycomed San Diego California 92120
Altana Pharma/Nycomed San Diego California 92123
Altana Pharma/Nycomed San Jose California 95117
Altana Pharma/Nycomed Stockton California 95207
Altana Pharma/Nycomed Walnut Creek, CA California 94598
Altana Pharma/Nycomed Coral Gables Florida 33134
Altana Pharma/Nycomed Ocala Florida 34471
Altana Pharma/Nycomed Atlanta Georgia 30342
Altana Pharma/Nycomed Gainesville Georgia 30501
Altana Pharma/Nycomed Savannah Georgia 31406
Altana Pharma/Nycomed Normal Illinois 61761
Altana Pharma/Nycomed Indianapolis Indiana 46208
Altana Pharma/Nycomed Dubuque Iowa 52001
Altana Pharma/Nycomed Overland Park Kansas 66210
Altana Pharma/Nycomed Metairie Louisiana 70001
Altana Pharma/Nycomed Shreveport Louisiana 71130
Altana Pharma/Nycomed Rockville Maryland 20850
Altana Pharma/Nycomed Wheaton Maryland 20902
Altana Pharma/Nycomed North Dartmouth Massachusetts 02747
Altana Pharma/Nycomed Minneapolis Minnesota 55402
Altana Pharma/Nycomed Jefferson City Missouri 65101
Altana Pharma/Nycomed Rolla, Mo Missouri 65401
Altana Pharma/Nycomed St Louis Missouri 63141
Altana Pharma/Nycomed Papillion Nebraska 68046
Altana Pharma/Nycomed Brick New Jersey 08724
Altana Pharma/Nycomed Skillman New Jersey 08558
Altana Pharma/Nycomed Liverpool New York 13088
Altana Pharma/Nycomed Raleigh North Carolina 27607
Altana Pharma/Nycomed Canton Ohio 44718
Altana Pharma/Nycomed Cincinnati, OH Ohio 45231
Altana Pharma/Nycomed Sylvania Ohio 43560
Altana Pharma/Nycomed Medford Oregon 97504
Altana Pharma/Nycomed Portland Oregon 97213
Altana Pharma/Nycomed Easton Pennsylvania 18045
Altana Pharma/Nycomed Hershey Pennsylvania 17033
Altana Pharma/Nycomed Upland Pennsylvania 19013
Altana Pharma/Nycomed Charleston South Carolina 29407
Altana Pharma/Nycomed Charleston South Carolina 29414
Altana Pharma/Nycomed Moncks Corner South Carolina 29461
Altana Pharma/Nycomed Spartanburg South Carolina 29307
Altana Pharma/Nycomed Austin Texas 78750
Altana Pharma/Nycomed El Paso Texas 79925
Altana Pharma/Nycomed Fort Worth Texas 76132
Altana Pharma/Nycomed Friendswood Texas 77546
Altana Pharma/Nycomed Houston Texas 77054
Altana Pharma/Nycomed Katy Texas 77450
Altana Pharma/Nycomed Salt Lake City Utah 84037
Altana Pharma/Nycomed South Burlington Vermont 05403
Altana Pharma/Nycomed Burke Virginia 22015
Altana Pharma/Nycomed Richmond Virginia 23219
Altana Pharma/Nycomed Richmond Virginia 23226
Altana Pharma/Nycomed Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00163514, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00163514 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →